Drug Truths (eBook)
152 Seiten
John Wiley & Sons (Verlag)
978-1-118-15896-8 (ISBN)
pharmaceutical R & D in a compelling narrative focused on the
discovery and development of important new medicines. It gives an
insider's account of the pharmaceutical industry drug discovery
process, the very real costs of misperceptions about the industry,
the high stakes--both economic and scientific--of developing drugs,
the triumphs that come when new compounds reach the market and save
lives, and the despair that follows when new compounds fail. In the
book, John LaMattina, former president of Pfizer Global Research
and Development, weaves themes critical to a vital drug discovery
environment in the context. This is a story that Dr. LaMattina is
uniquely qualified to tell.
John L. LaMattina, PhD, retired as president of Pfizer Global Research and Development in 2007 where he managed more than 13,000 scientists and support professionals in the United States, Europe, and Asia. Dr. LaMattina has received numerous awards including an Honorary Doctor of Science degree from the University of New Hampshire.
ACKNOWLEDGMENTS ix
INTRODUCTION xi
PART I A MATTER OF THE HEART 1
CHAPTER 1 CHOLESTEROL DRUGS ARE UNNECESSARY 3
CHAPTER 2 INDUSTRY IS MORE INTERESTED IN "ME-TOO" DRUGS THAN IN INNOVATION 13
CHAPTER 3 IT TAKES INDUSTRY TOO LONG TO DISCOVER NEW DRUGS 23
PART II THE ROLE OF PHARMACEUTICAL R&D IN HEALTH CARE 39
CHAPTER 4 DRUGS ARE DISCOVERED BY ACADEMIA 41
CHAPTER 5 NEW MEDICINES ADD COSTS BUT LITTLE BENEFIT 50
CHAPTER 6 BIG PHARMA HAS FAILED AND SHOULD LEARN FROM BIOTECH SUCCESS 59
PART III THE PROFIT MOTIVE 69
CHAPTER 7 THE INDUSTRY INVENTS DISEASES 71
CHAPTER 8 NEW DRUGS ARE LESS SAFE THAN TRADITIONAL MEDICINES 79
CHAPTER 9 INDUSTRY SPENDS MORE ON ADVERTISING THAN ON R&D 91
CHAPTER 10 INDUSTRY DOES NOT CARE ABOUT DISEASES OF THE DEVELOPING WORLD 100
PART IV THE FUTURE 109
CHAPTER 11 BIG PHARMA'S DAY HAS PASSED 111
CHAPTER 12 FINAL REFLECTIONS 122
REFERENCES 124
INDEX 133
?This book, a concise and reasonably priced text, is a must-read
for anyone working in the pharmaceutical industry. However, it is
not just written for scientist, anyone interested in learning more
about the big issues facing pharmaceutical research and development
and global healthcare today should find this book
thought-provoking.? (Pharmaceutical Journal, September 2009)
?Drug Truths: Dispelling the Myths About Pharma R & D
is an generally persuasive argument for the soul of the
pharmaceutical industry.? (Journal of Clinical Research Best
Practices, December 2009)
"I would recommend this book." (Chemistry World, June
2009)
"LaMattina stands out from many of the other observers of the
industry." (Nature Chemistry, May 2009)
"The book provides unique insights into how big pharma manages
its R&D. It also serves as a reminder of the useful role the
drug industry play in keeping us healthy." (Chemical &
Engineering News, April 20, 2009)
?The book offers an insider?s account of the reality of the drug
discovery process?revealing it to be more risky, complicated and
expensive than many critics suggest. Chapter by chapter, LaMattina
addresses the common misconceptions about the pharmaceutical
industry?setting the record straight.? (Kansas City
InfoZine, February 2009)
?Along with a careful dissection of each false claim and a
presentation of the overwhelming evidence that disproves it,
LaMattina offers fascinating explanations of the way drug
development and government approval function ? relying not on
clever rhetoric, but on scientific fact and reliable evidence to
support his claims; all the while remaining realistic about the
industry's limitations.? (Medical News Today, February
2009)
"It's obvious from reading his book that LaMattina believes in
his industry, in Big Pharma, and in the research and development
that has led to drugs that have cured infectious diseases, delayed
encroaching heart disease, controlled arthritis?for many
millions?reduced pain and suffering." (TheDay.com, January
25, 2009)
"John L. LaMattina ... the recently retired head of
Pfizer's global research and development... by using well
illustrated examples, takes us through the realities and myths
about many of the issues surrounding the pharmaceutical industry.
Rather than innuendo, he offers data. This is an important and
timely book ... In the end this book is about science where
data rules. ... [and] should become indispensable to those who
wish to either understand or set policy."
--Dr. Richard A. Lerner, President of The Scripps Research
Institute
"Drug Truths is an authoritative, clear and accessible
exposition of the realities of drug discovery and development. It
is factual and balanced, although LaMattina does not shy away from
criticizing some of the misguided views that have appeared in
print. The main points are well documented and logically presented.
The book is a splendid addition to the contemporary health care
literature."
--E. J. Corey, Harvard University
Erscheint lt. Verlag | 2.3.2012 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Pharmazie |
Naturwissenschaften ► Chemie | |
Technik | |
Wirtschaft | |
Schlagworte | Arzneimittelentwicklung • Biochemie u. Chemische Biologie • Biochemistry (Chemical Biology) • Chemie • Chemistry • Drug Discovery & Development • Forschung und Entwicklung • Medical Science • Medizin • Pharmacology & Pharmaceutical Medicine • Pharmakologie • Pharmakologie u. Pharmazeutische Medizin • Wirkstoffforschung u. -entwicklung |
ISBN-10 | 1-118-15896-2 / 1118158962 |
ISBN-13 | 978-1-118-15896-8 / 9781118158968 |
Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
Haben Sie eine Frage zum Produkt? |
Größe: 3,1 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich